Source comparison
Best Thymosin Alpha-1 Dosage Autoimmune Support 2026: Clinical Evidence Comparison
Hashimoto's Thyroiditis 1.6mg 3× weekly 12–24 weeks 38% reduction in anti-TPO antibodies; TSH normalisation in 64% of patients (Thyroid Research 2021) Best-documented protocol; strong evidence for antibody reduction and thyroid function stabilisation Systemic
This comparison does not assign a generated winner or score.
- Hashimoto's Thyroiditis
- 1.6mg
- 3× weekly
- 12–24 weeks
- 38% reduction in anti-TPO antibodies; TSH normalisation in 64% of patients (Thyroid Research 2021)
- Best-documented protocol; strong evidence for antibody reduction and thyroid function stabilisation
- Systemic Lupus Erythematosus (SLE)
- 3.2–6.4mg
- 2× weekly
- 24 weeks
- Anti-dsDNA titre reduction, improved SLEDAI scores, complement normalisation (Peking Union 2020)
- Higher dosing justified by systemic disease burden; works as add-on to conventional therapy
- Rheumatoid Arthritis
- 1.6–3.2mg
- 2–3× weekly
- 16–20 weeks
- ACR20 response improved from 48% to 71% when added to methotrexate (Autoimmunity Reviews 2022)
- Effective adjunct therapy; reduces Th17-driven inflammation while promoting Treg expansion
- Psoriatic Arthritis
- 3.2mg
- 16 weeks
- PASI score reduction of 42% from baseline in small pilot trial (Journal of Dermatological Treatment 2023)
- Emerging evidence; larger trials needed but mechanism aligns with Th17/Treg rebalancing
- Multiple Sclerosis (Relapsing-Remitting)
- 24–48 weeks
- Reduced relapse rate and MRI lesion load in open-label study (Multiple Sclerosis Journal 2019)
- Preliminary data only; not yet validated in Phase III trials